Pre-eclampsia is a serious blood pressure condition that can develop during pregnancy, usually after 20 weeks of gestation. Managing this condition requires careful medical supervision, specialized treatment approaches, and sometimes early delivery of the baby to protect both mother and child from potentially life-threatening complications.

Managing a Complex Pregnancy Challenge

When pre-eclampsia develops during pregnancy, the primary goal of treatment is to protect the health and safety of both the pregnant woman and her developing baby. This pregnancy complication, characterized by high blood pressure and signs of organ damage, affects between 2% and 8% of pregnancies worldwide. While many women with pre-eclampsia go on to have healthy babies, the condition requires immediate medical attention and careful management to prevent serious complications.^[1][2]

The treatment approach for pre-eclampsia depends heavily on several key factors. These include how far along the pregnancy is, how severe the condition has become, and the overall health status of both mother and baby. Healthcare providers must carefully balance the need to allow the baby more time to develop in the womb against the risks that continuing the pregnancy poses to the mother’s health. In some cases, medical management and close monitoring allow pregnancy to continue safely for weeks or even months. In other situations, particularly when pre-eclampsia becomes severe, immediate delivery may be necessary regardless of how early in pregnancy it occurs.^[5][10]

Medical societies and healthcare organizations have established detailed guidelines for managing pre-eclampsia, based on decades of research and clinical experience. These guidelines help doctors decide when to monitor closely, when to prescribe medication, and when delivery is the safest option. Alongside these established treatments, researchers are also investigating new therapies in clinical trials, seeking better ways to predict, prevent, and treat this potentially dangerous condition.

Standard Medical Treatment for Pre-eclampsia

The cornerstone of standard pre-eclampsia treatment revolves around three main approaches: careful monitoring of mother and baby, medications to control blood pressure and prevent complications, and timely delivery when necessary. The specific combination of these approaches depends on whether the pre-eclampsia is classified as having severe features or not.

For women diagnosed with pre-eclampsia without severe features before 37 weeks of pregnancy, doctors typically recommend close monitoring rather than immediate delivery. This expectant management approach involves frequent prenatal visits, often daily or several times per week, to check blood pressure and assess both maternal and fetal well-being. During these visits, healthcare providers measure blood pressure, test urine for protein levels, and perform blood tests to check kidney and liver function. Tests to monitor the baby’s health, such as non-stress tests (which measure the baby’s heart rate patterns) and ultrasound examinations (which assess fetal growth and the amount of fluid surrounding the baby), are performed regularly.^[9][13]

When pre-eclampsia reaches or passes 37 weeks of gestation, delivery is typically recommended even if the condition remains mild. At this point, the baby is considered full-term and the risks of continuing the pregnancy outweigh the benefits of waiting longer. Labor may be induced artificially using medications, or a cesarean section may be performed depending on standard obstetric considerations.^[13]

Blood pressure medications form a critical part of pre-eclampsia treatment. When blood pressure readings consistently reach 140/90 mm Hg or higher, or when readings climb to the severe range of 160/110 mm Hg or higher, doctors prescribe medications to bring blood pressure down to safer levels. The most commonly used blood pressure medications during pregnancy include labetalol (a beta-blocker), nifedipine (a calcium channel blocker), and methyldopa. Of these, labetalol is specifically licensed for use in pregnant women with high blood pressure in many countries. The other medications, while not always specifically approved for pregnancy use, have been used safely for many years and are recommended by medical guidelines when appropriate.^[10][13]

These medications work through different mechanisms to lower blood pressure. Labetalol blocks certain receptors in the body that respond to stress hormones, causing blood vessels to relax and blood pressure to decrease. Nifedipine prevents calcium from entering the muscle cells of blood vessel walls, which also causes the vessels to relax and widen. Methyldopa works in the brain to reduce the signals that cause blood vessels to tighten. Doctors choose which medication to use based on individual patient factors, including how well blood pressure responds and whether any side effects occur.

When pre-eclampsia develops severe features, more intensive treatment becomes necessary. Severe features include very high blood pressure (160/110 mm Hg or higher), signs of kidney or liver damage detected through blood tests, low levels of blood platelets (the cells that help blood clot), fluid in the lungs making breathing difficult, or symptoms such as severe headaches and vision problems. Women with severe pre-eclampsia are typically admitted to the hospital for close monitoring and treatment.^[9][11]

One of the most important medications used in severe pre-eclampsia is magnesium sulfate. This medication helps prevent seizures, a dangerous complication called eclampsia that can occur when pre-eclampsia becomes very severe. Magnesium sulfate is given through an intravenous line (a tube inserted into a vein) and is continued during labor and for 24 hours after delivery. Studies have shown that magnesium sulfate reduces the risk of eclampsia by more than half. Despite its proven effectiveness, magnesium sulfate is still not used as widely as it should be in some parts of the world with limited medical resources.^[8][13]

While receiving magnesium sulfate, women may experience side effects such as feeling warm or flushed, muscle weakness, or drowsiness. Healthcare providers monitor patients closely during magnesium sulfate treatment, checking reflexes and watching for signs that magnesium levels might be becoming too high. The medication is generally safe when properly monitored, and its benefits in preventing life-threatening seizures far outweigh the temporary discomfort of side effects.

For women who develop severe pre-eclampsia before 34 weeks of pregnancy, doctors may give corticosteroid injections to help the baby’s lungs mature more quickly. These medications, typically betamethasone or dexamethasone, are given in two doses 24 hours apart. They significantly improve outcomes for premature babies by reducing complications related to underdeveloped lungs. After giving corticosteroids, doctors may try to delay delivery for 48 hours if the mother’s condition remains stable, allowing time for the medications to take full effect.^[5][13]

The timing and method of delivery in severe pre-eclampsia requires careful consideration. Generally, delivery is recommended after 34 weeks of pregnancy when severe features develop. However, if the mother’s condition becomes critically unstable—for example, if blood pressure cannot be controlled, kidney or liver function deteriorates rapidly, or the baby shows signs of severe distress—delivery may be necessary immediately, even earlier in pregnancy. The decision involves weighing the serious risks of continuing the pregnancy against the challenges a premature baby will face.^[11][13]

After delivery, pre-eclampsia usually improves within days to weeks. However, blood pressure may remain elevated for some time, and women often need to continue taking blood pressure medications for several weeks after giving birth. Healthcare providers monitor blood pressure regularly after delivery and adjust medications as needed. In rare cases, pre-eclampsia can develop for the first time after delivery, a condition called postpartum pre-eclampsia. This typically occurs within 48 hours of delivery but can occasionally happen up to six weeks later. Women should remain alert to symptoms even after returning home with their babies.^[1][10]

Prevention Strategies: Low-Dose Aspirin

While most treatments for pre-eclampsia focus on managing the condition once it develops, one preventive approach has proven effective for women at high risk: taking low-dose aspirin starting early in pregnancy. For women with certain risk factors, healthcare providers may recommend taking between 75 and 150 milligrams of aspirin daily, beginning between 12 and 28 weeks of pregnancy (ideally before 16 weeks) and continuing until the baby is born.^[4][6]

Low-dose aspirin works by affecting substances in the blood called prostaglandins, which influence blood clotting and blood vessel function. By subtly changing how these substances work, aspirin may help prevent the abnormal placental development thought to contribute to pre-eclampsia. Research has shown that low-dose aspirin can reduce the risk of developing pre-eclampsia in high-risk women, though it does not eliminate the risk entirely.

Women who may benefit from low-dose aspirin include those with a history of pre-eclampsia in a previous pregnancy, those with chronic high blood pressure or kidney disease, those with diabetes, women carrying twins or triplets, and those with certain autoimmune conditions. Healthcare providers assess each woman’s individual risk factors during early pregnancy and recommend aspirin when appropriate. It is important that women take low-dose aspirin exactly as prescribed—neither more often nor in higher doses than recommended—since taking too much aspirin can cause problems.^[6]

Emerging Treatments in Clinical Research

While effective standard treatments exist for managing pre-eclampsia, researchers continue investigating new approaches that might better predict, prevent, or treat this condition. Clinical trials around the world are testing innovative therapies based on growing understanding of the biological mechanisms underlying pre-eclampsia.

Much of the research into new treatments stems from current theories about what causes pre-eclampsia. Scientists believe the condition begins with abnormal development of the placenta early in pregnancy. In healthy pregnancies, blood vessels in the placenta undergo dramatic changes that allow them to deliver large volumes of blood to the growing baby. In pre-eclampsia, this process goes wrong—the blood vessels don’t develop properly, leading to reduced blood flow. The struggling placenta releases substances into the mother’s bloodstream that affect blood vessels throughout her body, causing high blood pressure and organ damage.^[3][14]

One promising area of research focuses on substances called angiogenic factors—proteins that regulate the growth and function of blood vessels. In pre-eclampsia, the balance of these factors becomes disturbed. Specifically, levels of beneficial factors that promote healthy blood vessel function decrease, while levels of harmful factors that impair blood vessel function increase. Scientists are investigating whether treatments that restore the normal balance of angiogenic factors might prevent or treat pre-eclampsia. Some experimental approaches being studied in clinical trials include giving synthetic versions of beneficial angiogenic factors or using medications to block the harmful ones.

Researchers have also been investigating whether certain vitamins and supplements might help prevent pre-eclampsia. Studies have looked at antioxidant vitamins such as vitamin C and vitamin E, based on the theory that oxidative stress (a type of cellular damage) may contribute to pre-eclampsia. However, large clinical trials testing these supplements have generally not shown significant benefits, and current medical guidelines do not recommend routine use of vitamin supplements beyond standard prenatal vitamins for preventing pre-eclampsia.

Another research direction involves identifying women at high risk for developing pre-eclampsia through sophisticated biomarker testing. In 2023, the U.S. Food and Drug Administration approved a blood test that measures certain proteins to help predict which women are at increased risk of developing pre-eclampsia within the next two weeks. Such tests could help doctors identify women who need especially close monitoring or more aggressive preventive treatment. Additional biomarker tests are under investigation in clinical trials, including tests that examine genetic factors, immune system markers, and various proteins released by the placenta.^[20]

Some research has explored whether medications that affect the immune system might help prevent or treat pre-eclampsia. This approach stems from evidence that immune system dysfunction may play a role in abnormal placental development. However, these therapies remain experimental and are being tested in early-phase clinical trials to determine if they are safe and potentially effective.

Researchers are also investigating whether certain dietary interventions might help prevent pre-eclampsia. Some studies have looked at calcium supplementation, especially in populations where dietary calcium intake is typically low. Evidence suggests that calcium supplementation may reduce pre-eclampsia risk in women who have inadequate calcium intake, though the benefit appears less clear in well-nourished populations.

Clinical trials investigating new treatments for pre-eclampsia take place in multiple phases. Phase I trials test whether a new treatment is safe, typically involving small numbers of participants. Phase II trials examine whether the treatment shows signs of being effective and continue to monitor safety, usually with larger groups of participants. Phase III trials compare the new treatment directly against standard treatment in large numbers of patients to definitively determine whether the new approach is better, equivalent, or inferior to existing options. Trials for pre-eclampsia treatments occur in many countries, including the United States, European nations, and increasingly in other regions around the world.

Women interested in participating in clinical trials for pre-eclampsia prevention or treatment should discuss this option with their healthcare providers. Participation in trials contributes valuable information to medical science while potentially providing access to promising new therapies. However, experimental treatments always carry uncertainty, and participation should be a carefully considered decision made with full information about potential benefits and risks.

Most common treatment methods

• Blood pressure medications
  • Labetalol (a beta-blocker) specifically licensed for pregnancy use in many countries
  • Nifedipine (a calcium channel blocker) used to relax blood vessel walls
  • Methyldopa, which works through the brain to reduce blood pressure
  • Prescribed when blood pressure reaches 140/90 mm Hg or higher
  • May be continued for several weeks after delivery until blood pressure normalizes
• Magnesium sulfate for seizure prevention
  • Given intravenously to prevent eclampsia (seizures) in severe pre-eclampsia
  • Reduces the risk of eclampsia by more than half
  • Administered during labor and for 24 hours after delivery
  • Requires close monitoring for side effects and magnesium levels
• Corticosteroid injections
  • Betamethasone or dexamethasone given before 34 weeks of pregnancy
  • Helps mature the baby’s lungs in case of early delivery
  • Given as two doses 24 hours apart
  • Significantly improves outcomes for premature babies
• Careful monitoring
  • Frequent blood pressure measurements at prenatal visits
  • Regular urine tests to check protein levels
  • Blood tests to monitor kidney and liver function and platelet counts
  • Ultrasound examinations to assess fetal growth and amniotic fluid levels
  • Non-stress tests and other fetal monitoring to check baby’s well-being
  • May require daily visits or hospitalization for severe cases
• Timely delivery
  • Recommended at 37 to 38 weeks for pre-eclampsia without severe features
  • May be necessary after 34 weeks when severe features develop
  • Can require immediate delivery at any gestational age if mother’s life is in danger
  • May involve induced labor or cesarean section depending on circumstances
  • The only definitive cure for pre-eclampsia
• Low-dose aspirin for prevention
  • 75 to 150 milligrams daily for women at high risk
  • Started between 12 and 28 weeks of pregnancy, ideally before 16 weeks
  • Continued until delivery
  • Reduces risk of developing pre-eclampsia in high-risk women
  • Recommended for women with previous pre-eclampsia, chronic high blood pressure, kidney disease, diabetes, multiple pregnancies, or certain autoimmune conditions

Long-Term Health Implications

The impact of pre-eclampsia extends far beyond pregnancy and delivery. Women who have experienced pre-eclampsia face significantly increased risks for cardiovascular disease later in life. This includes higher rates of chronic high blood pressure, stroke, heart failure, heart attack, and peripheral vascular disease (blocked arteries in the legs). Research shows that women who had pre-eclampsia are at least twice as likely as women with normal pregnancies to develop heart disease in the future.^[20][21]

Medical experts now view pre-eclampsia as an important warning sign—sometimes called a “failed stress test” for the cardiovascular system. The same factors that led to pre-eclampsia during pregnancy, such as blood vessel dysfunction and inflammation, may continue affecting a woman’s health long after pregnancy ends. Additionally, women who develop pre-eclampsia may have underlying risk factors for heart disease that were present before pregnancy but only became apparent when pregnancy placed extra demands on the cardiovascular system.

Because of these long-term risks, medical organizations now recommend that women with a history of pre-eclampsia receive cardiovascular risk screening and counseling. This should include checking blood pressure regularly, testing cholesterol and blood sugar levels, maintaining a healthy weight, exercising regularly, and not smoking. Many experts recommend that this cardiovascular risk assessment begin within a year after delivery, rather than waiting until later in life when screening typically begins for women without pregnancy complications. Early identification and management of cardiovascular risk factors can help prevent or delay the development of serious heart and blood vessel diseases.^[20]

Women who have had pre-eclampsia should make sure all their healthcare providers, including primary care doctors and cardiologists, know about this history. This information helps doctors better assess overall health risks and make appropriate recommendations for screening, lifestyle modifications, and possibly preventive medications. Viewing pre-eclampsia not just as a pregnancy complication but as a marker for lifelong cardiovascular health allows women and their doctors to take proactive steps to protect health for decades to come.